04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
18:40 , Mar 12, 2019 |  BC Extra  |  Financial News

InventisBio raises $70M series C to advance early stage pipeline

InventisBio raised $70 million in a series C round led by Advantech Capital and CMBI, the Chinese biotech announced late Monday. Pudong Innotek and existing investors Lilly Asia Ventures and OrbiMed Asia also participated in...
18:42 , Mar 8, 2019 |  BC Extra  |  Company News

TNBC gets its first targeted agent with Tecentriq approval

The approval of Roche's Tecentriq atezolizumab to treat metastatic triple-negative breast cancer gives almost half of these patients and physicians' their first agent to treat a molecularly defined subgroup of patients with this fast-progressing cancer....
02:47 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
23:22 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture studies identified a selective degrader of ESR1 that could help treat estrogen receptor-positive breast cancer. Chemical synthesis and testing in human estrogen receptor-positive breast cancer lines of analogs of the...
00:38 , Feb 8, 2019 |  BC Innovations  |  Product R&D

Reducing R(i)SK in TNBC

Phoenix Molecular Designs could provide triple-negative breast cancer its first molecular marker to turn the intractable indication from a group of have-nots to a group of haves. With early evidence that RSK2 is activated in...
16:12 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting P4HA1 could help treat triple-negative breast cancer (TNBC). In tumor samples from TNBC patients, levels of P4HA1 protein were higher than in samples from estrogen...
18:50 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest PEGylated ARG1 and dichloroacetate could help treat breast cancer. In a human triple-negative breast cancer (TNBC) and a human estrogen receptor-positive breast cancer cell line, the...
19:18 , Nov 1, 2018 |  BC Innovations  |  Translation in Brief

Private sharing

A new cryptographic computational protocol from the Massachusetts Institute of Technology will allow drug companies to pool data for predictive modeling of drug-target interactions without revealing the underlying drugs, targets or observed interactions. The method...
17:58 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast Cancer Patient sample, cell culture and mouse studies suggest inhibiting ANKLE2 could help treat breast cancer. In breast cancer patients, high tumor levels of ANKLE2 were associated with disease progression and poor overall...